Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation (vol 109, pg 1149, 2024)

被引：0

作者：

Epstein-Peterson, Zachary D. ^{[1
]}

Drill, Esther ^{[2
]}

Aypar, Umut ^{[3
]}

Batlevi, Connie Lee ^{[1
]}

Caron, Philip ^{[1
]}

Dogan, Ahmet

Drullinsky, Pamela ^{[1
]}

Gerecitano, John ^{[1
,6
]}

Hamlin, Paul A. ^{[1
]}

Ho, Caleb ^{[3
,7
]}

Jacob, Allison ^{[4
]}

Joseph, Ashlee ^{[1
]}

Laraque, Leana ^{[1
]}

Matasar, Matthew J. ^{[1
]}

Moskowitz, Alison J. ^{[1
]}

Moskowitz, Craig H. ^{[1
,9
]}

Mullins, Chelsea ^{[4
,8
]}

Owens, Colette ^{[1
]}

Salles, Gilles ^{[1
]}

Schoder, Heiko ^{[5
]}

Straus, David J. ^{[1
]}

Younes, Anas ^{[1
,10
]}

Zelenetz, Andrew D. ^{[1
]}

Kumar, Anita ^{[1
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, Dept Med, Lymphoma Serv, Div Hematol Malignancies, New York, NY 10065 USA

[2] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY USA

[3] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY USA

[4] Adapt Biotechnol, Seattle, WA USA

[5] Mem Sloan Kettering Canc Ctr, Dept Radiol, New York, NY USA

[6] Janssen Pharmaceut Co Johnson & Johnson, Raritan, NJ USA

[7] Loxo Oncol Inc, Stamford, CT USA

[8] Notch Therapeut, Seattle, WA USA

[9] Univ Miami, Sylvester Comprehens Canc Ctr, Dept Med, Div Hematol,Miller Sch Med, Miami, FL USA

[10] AstraZeneca Pharmaceut LP, Wilmington, DE USA

来源：

HAEMATOLOGICA | 2024年 / 109卷 / 08期

关键词：

D O I：

10.3324/haematol.2024.285845

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：4

共 30 条

[21] frontMIND: A phase III, randomized, double-blind study of tafasitamab plus lenalidomide plus R-CHOP versus R-CHOP alone for newly diagnosed high-intermediate and high-risk diffuse large B-cell lymphoma.
Vitolo, Umberto
Nowakowski, Grzegorz S.
Burke, John M.
Fox, Christopher P.
Trneny, Marek
Chiappella, Annalisa
Waldron-Lynch, Maeve
Hadar, Nira
Pachori, Alok
Lenz, Georg
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[22] Phase II study of durvalumab (anti-PD-L1 antibody) in combination with R-CHOP or lenalidomide plus R-CHOP in previously untreated, high-risk diffuse large B-cell lymphoma.
Nowakowski, Grzegorz S.
Kalakonda, Nagesh
Truemper, Lorenz
Everaus, Hele
Fustier, Pierre
Jaeger, Jonathan
Manzke, Oliver
Jager, Ulrich
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[23] Depth of response and minimal residual disease status in ultra high-risk multiple myeloma and plasma cell leukemia treated with daratumumab, bortezomib, lenalidomide, cyclophosphamide and dexamethasone (Dara-CVRd): Results of the UK optimum/MUKnine trial.
Kaiser, Martin F.
Hall, Andrew
Walker, Katrina
De Tute, Ruth
Roberts, Sadie
Ingleson, Emma
Bowles, Kristian
Garg, Mamta
Lokare, Anand
Messiou, Christina
Jackson, Graham H.
Pratt, Guy
Cook, Gordon
Drayson, Mark
Owen, Roger G.
Brown, Sarah R.
Jenner, Matthew
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[24] Nordic MCL2 Trial Update: 6-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC Plus autologous stem-cell support: still very long survival but late relapses do occur (vol 158, pg 355, 2012)
Geisler, Christian H.
Kolstad, Arne
Laurell, Anna
Jerkeman, Mats
Raty, Riikka
Andersen, Niels S.
Pedersen, Lone B.
Eriksson, Mikael
Nordstrom, Marie
Kimby, Eva
Bentzen, Hans
Kuittinen, Outi
Lauritzsen, Grete F.
Nilsson-Ehle, Herman
Ralfkiaer, Elisabeth
Ehinger, Mats
Sundstrom, Christer
Delabie, Jan
Karjalainen-Lindsberg, Marja-Liisa
Brown, Peter
Elonen, Erkki
BRITISH JOURNAL OF HAEMATOLOGY, 2012, 158 (06) : 815 - 816
[25] Disease-free Survival Analysis for Patients with High-risk Muscle-invasive Urothelial Carcinoma from the Randomized CheckMate 274 Trial by PD-L1 Combined Positive Score and Tumor Cell Score (vol 83, pg 432, 2024)
Galsky, Matthew D.
Bajorin, Dean F.
Witjes, Johannes Alfred
Gschwend, Juergen E.
Tomita, Yoshihiko
Nasroulah, Federico
Li, Jun
Collette, Sandra
Valderrama, Begona P.
Grimm, Marc-Oliver
Appleman, Leonard
Gravis, Gwenaelle
Necchi, Andrea
Ye, Dingwei
Stenner, Frank
Wind-Rotolo, Megan
Zhang, Joshua
uensal-Kacmaz, Keziban
EUROPEAN UROLOGY, 2024, 85 (03) : e96 - e97
[26] FRONT-MIND: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Comparing Efficacy and Safety of Tafasitamab plus Lenalidomide plus R-CHOP vs R-CHOP Alone for Newly-Diagnosed High-Intermediate and High-Risk Diffuse Large B-Cell Lymphoma (DLBCL)
Vitolo, Umberto
Nowakowski, Grzegorz S.
Burke, John M.
Fox, Christopher P.
Trneny, Marek
Chiappella, Annalisa
Tillmanns, Sascha
Sporchia, Andrea
Brugger, Wolfram
Lenz, Georg
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S376 - S377
[27] Epcoritamab plus R-DHAX/C Induces Deep, Durable Responses in Transplant-Eligible Patients With Relapsed or Refractory (R/R) Diffuse Large B- Cell Lymphoma (DLBCL), Including High-Risk Disease
Abrisqueta, Pau
Falchi, Lorenzo
Nijland, Marcel
de Vos, Sven
Offner, Fritz
Rana, Ali
Archer, Kimberly
Song, Yaou
Osei-Bonsu, Kojo
Karimi, Yasmin
Cordoba, Raul
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S468 - S468
[28] Early Achievement of Deep Measurable Residual Disease (MRD) Negativity Identifies Patients with B-Cell Acute Lymphoblastic Leukemia (ALL) Who Have Excellent Long-Term Outcomes and Do Not Benefit from Allogeneic Stem Cell Transplant, Irrespective of Baseline High-Risk Cytomolecular Features
Macaron, Walid
Jabbour, Elias
Jain, Nitin
Haddad, Fadi G.
Senapati, Jayastu
Kebriaei, Partow
Kugler, Eitan
Chien, Kelly S.
Issa, Ghayas C.
Matthews, Jairo
Garris, Rebecca
Ravandi, Farhad
Kantarjian, Hagop M.
Short, Nicholas J.
BLOOD, 2024, 144 : 727 - 728
[29] Usefulness of exercise thallium-201 imaging in evaluation of low-and high-risk groups in coronary artery disease patients with disappearance of anginal episodes by anti-anginal drug therapy (vol 39, pg 597, 1998)
Hanashi, A
JAPANESE HEART JOURNAL, 1999, 40 (04): : U1 - U1
[30] Circulating Tumor DNA Analysis Associates with Progression- Free Survival ( PFS) with Odronextamab Monotherapy in Relapsed/Refractory (R/ R) Follicular Lymphoma (FL) and Diffuse Large B-Cell Lymphoma (DLBCL): Identification of Minimal Residual Disease Status and High-Risk Subgroups from the Phase 2 ELM-2 Study
Arnason, Jon E.
Brouwer-Visser, Jurriaan
Luminari, Stefano
Tucker, David
Kim, Tae Min
Kim, Won Seog
Magnano, Laura
Sun, Dylan
Cai, Jessica
Cygan, Kamil
Ambati, Srikanth
Mohamed, Hesham
Chaudhry, Aafia
Jankovic, Vladimir
BLOOD, 2023, 142

← 1 2 3 →